Amgen

Open: 224.21 Close: 224.44 Change: 0.23

Are you still looking for information about Amgen Company Inc? An AI summarized it for you.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, patent, Horizon, drug, Court, deal, and the most common words in the summary are: amgen, stock, market, horizon, news, price, inc, . One of the sentences in the summary was: Supreme Court rules against Amgen bid to revive cholesterol drug patents. Other searches related …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents. Food and Drug Administration could approve Amgens biosimilar in second or third quarter of 2023.

Today's News

Amgen sought to collect millions of dollars in damages in a lawsuit dating back nine years. Sanofi wins supreme court patent dispute with amgen - wsj. Sanofi Wins Supreme Court Patent Dispute With Amgen. Horizon Therapeutics-Amgen deal could close Q3 if ftc block fails. California-based Amgens stock price dipped 1% lower. If completed, the deal would give Amgen access to Horizons blockbuster thyroid eye disease drug, Tepezza and its gout medicine Krystexxa. Amgen settles patent lawsuit over biosimilar of J&Js big-selling Stelara for psoriasis and other autoimmune conditions. Food and Drug Administration could approve Amgens biosimilar in second or third quarter of 2023. The Court held, as many feared they would, that the 26 antibody examples and detailed instructions for generating additional antibodies within the genus were insufficient. U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents. Small- and mid-cap biotech stocks under pressure following FTC decision to sue over proposed merger between Amgen and Horizon Therapeutics. U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents. The 9-0 ruling upheld a lower courts decision that had invalidated Amgens patents. Federal Trade Commission faces uphill battle in its fight with Amgen. U.S. Supreme Court rules against Amgen in Cholesterol Drug Patent Dispute with Sanofi/ Regeneron. Ideaya announces FDA nod to run Amgen-sponsored tumor study. The FTC announced on May 16 that it had filed the lawsuit because of concerns the deal could give Amgen monopoly pricing power over two potential blockbuster drugs that Horizon has developed. In response, Amgen said it was disappointed in the FTC decision. Amgen settles J&J patent lawsuit over drug similar to blockbuster Stelara. U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents. FTC faces uphill battle in its fight to block Amgens $27.8 billion takeover of Horizon Therapeutics. FTC sues to block Amgens $27.8 billion acquisition of Horizon Therapeutics Plc in rare move to block a large pharmaceutical deal. Jefferies managing director, Michael Yee, expects Amgens Horizon Theraputics deal to go through despite FTC block. Federal Trade Commission (FTC) announced Tuesday that it will oppose the Amgen-Horizon deal on grounds it will stifle innovation and the development of new drugs. Amgen shares dipped about 2% from $233.53 to $229.90. Amgen Inc is a leader in biotechnology-based human therapeutics. The intrinsic value of one AMGN stock under the Base Case scenario is 219.71 USD. Amgen is overvalued by 2%. Wall Street analysts forecast AMGN stock price to rise over the next 12 months. Amgen Inc insiders have not bought any shares,and sold 2.1M USD worth of shares in the last 12 months. Amgen, Inc. (AMGN) stock has fallen 4.31% in a week. Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease. FTC says Amgen acquisition of Horizon Therapeutics would prevent other medicines from competing with Horizons Tepezza, a treatment approved by FDA for moderate to severe thyroid eye disease, and Krystexxa, a gout therapy. Amgen said it would not bundle Horizons products.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, patent, Horizon, drug, Court, deal, and the most common words in the summary are: amgen, stock, market, horizon, news, price, inc, . One of the sentences in the summary was: Supreme Court rules against Amgen bid to revive cholesterol drug patents. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #market #horizon #news #price #inc.